Bloodstream infection in patients with head and neck cancer: a major challenge in the cetuximab era.
M MarínCarlota GudiolF CastetM OlivaI PeiróC Royo-CebrecosJ CarratalàR MesiaPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2018)
BSI causes high mortality in patients with HNC and is most often secondary to pneumonia. It occurs mainly among patients with hypoalbuminemia who receive treatment with cetuximab or chemotherapy. The development of BSI in patients with HNC impairs their outcome, especially in the presence of hypoalbuminemia and comorbidities.